Backing Breakthroughs in Psychedelics
Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment.
Episode 5 of the Power to the Patients podcast, hosted by Brandon Li, titled "Backing Breakthroughs in Psychedelics" was published on June 6, 2025 and runs 39 minutes.
June 6, 2025 ·39m · Power to the Patients
Summary
Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment.
Episode Description
Similar Episodes
Feb 24, 2026 ·18m
Feb 24, 2026 ·18m